We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drug shortages continue to plague the U.S. healthcare system — a longstanding problem exacerbated by COVID-19-related trade interruptions, natural disasters, and ever-changing political landscapes. Read More
Ironwood Pharmaceuticals is acquiring VectivBio for $1.15 billion, netting a promising late-stage clinical asset aimed at treating severe, rare gastrointestinal conditions. Read More
The FTC announced Tuesday that it is suing to block Amgen from its intended $27.8 billion acquisition of Horizon Therapeutics, claiming the buy would create a monopoly on drugs used to treat two serious illnesses. Read More
Astellas Pharma has acquired Iveric Bio in a $5.9 billion deal that brings the Japanese biotech Iveric’s avacincaptad pegol (ACP), an investigational intraocular injection for geographic atrophy secondary to age-related macular degeneration. Read More
Akorn Pharmaceuticals is recalling dozens of unexpired human and animal drug products in connection with a Chapter 7 bankruptcy filing, ending a five-year struggle to stay afloat through court battles and regulatory enforcement actions. Read More
mRNA developer Moderna and computer giant IBM have announced an agreement under which Moderna will explore next-generation technologies, including quantum computing and artificial intelligence (AI), to accelerate mRNA research and science. Read More
Philips has struck a deal with Amazon Web Services (AWS) to offer its healthcare picture archiving and communication system on AWS’ artificial intelligence (AI)-driven cloud computing platform for an undisclosed financial amount. Read More
Merck announced Monday it will acquire Prometheus Biosciences in a nearly $11 billion deal expected to greatly expand the drugmaker’s portfolio of treatments for autoimmune diseases. Read More
Bristol Myers Squibb (BMS) and Pfizer have together filed separate lawsuits against two generic drugmakers, seeking to prevent the release of generic versions of Eliquis (apixaban), the blockbuster anticoagulant the pharma giants jointly developed. Read More
In a move to expand its offerings for cell and gene therapy developers, German biotech Sartorius has announced plans to purchase Polyplus for $2.6 billion, gaining access to the Strasbourg, France-based company’s viral vector production technology. Read More